Advertisement


Elizabeth J. Shpall, MD, and Nina Shah, MD—Mentor and Mentee: A Conversation

2017 ASCO Annual Meeting

Advertisement

Elizabeth J. Shpall, MD, of The University of Texas MD Anderson Cancer Center, and recipient of the 2017 Women Who Conquer Cancer Mentorship Award, discusses promoting women in oncology with Nina Shah, MD, of the University of California, San Francisco, the protégé who nominated Dr. Shpall for this recognition.



Related Videos

Head and Neck Cancer
Issues in Oncology

Maura L. Gillison, MD, PhD, on HPV and the Value of the Vaccine

Maura L. Gillison, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses her findings on the impact of prophylactic human papillomavirus vaccination on oral HPV infections among young adults in the United States. (Abstract 6003)

Breast Cancer
Survivorship

Matteo Lambertini, MD, on Pregnancy in Breast Cancer Patients: Results From a Multicenter Study

Matteo Lambertini, MD, of the Institut Jules Bordet, discusses a long-term follow-up analysis of the safety of pregnancy in patients with a history of estrogen receptor–positive breast cancer. (Abstract LBA10066)

Survivorship

Todd M. Gibson, PhD, on Childhood Cancer Survivors: Chronic Disease Trends

Todd M. Gibson, PhD, of St. Jude Children’s Research Hospital, discusses results from the Childhood Cancer Survivor Study, which showed a reduction in serious chronic morbidity measured across 3 decades. (LBA10500)

Breast Cancer

Lisa A. Carey, MD, and Nadia Harbeck, MD, PhD, on Early HER2-Negative Breast Cancer: Results of the PlanB Trial

Lisa A. Carey, MD, of the University of North Carolina, and Nadia Harbeck, MD, PhD, of Brustzentrum der Universität München, discuss study findings on adjuvant 4xEC→4x doc vs 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. (Abstract 504)

Kidney Cancer

Primo Lara, MD, on RCC: Expert Perspective on Three Key Papers

Primo Lara, MD, of the University of California, Davis Comprehensive Cancer Center, discusses three top abstracts on treating advanced renal cell carcinoma with epacadostat, pembrolizumab, atezolizumab, bevacizumab, sunitinib, or pazopanib. (Abstracts 4505, 4507, 4515)

Advertisement

Advertisement




Advertisement